Decline in immune function with age has been attributed to defects or alterations in both the innate and the adaptive immune system. This issue of the *JCI*, Zhao and coworkers provide evidence for a novel mechanism of immune dysfunction in aging mice. They show that migration of respiratory DCs from the site of virus replication to the draining lymph nodes in response to infection with several different respiratory viruses is markedly diminished with increasing age. The impaired DC migration was a result of increased levels of the lipid mediator prostaglandin D₂ (PGD₂) in the respiratory tract with age and could be partially reversed by blockade of PGD₂ synthesis or action.

Among the many hallmarks of the aging process (in both mice and humans) is a progressive decline in immune function (1, 2). This is demonstrable in the diminished response of the elderly to vaccination against viral and bacterial pathogens (1). This fact complicates the more serious problem of the increased susceptibility of the elderly to infection in general and to serious and frequently life-threatening infection of the respiratory tract with severe acute respiratory syndrome coronavirus (SARS-CoV). This decline in immune function with age has been attributed to defects or alterations in both the innate and the adaptive immune system (1, 2). In this issue of the *JCI*, Zhao and coworkers provide compelling evidence for a novel mechanism of immune dysfunction in aging mice (3). They demonstrate that the migration of respiratory DCs (RDCs) from the lungs to the lung draining lymph nodes (DLNs) in response to infection with several different respiratory viruses is markedly diminished with increasing age. Impaired RDC migration is mediated by the arachidonic acid (AA) metabolite prostaglandin D₂ (PGD₂), basal expression of which Zhao and coworkers show is increased in the respiratory tract with age and is further upregulated in response to infection in a pathogen-dependent fashion. They further demonstrate that blockade of either PGD₂ synthesis or action partially reverses the defect in RDC migration, resulting in an enhanced adaptive immune response to infection and increased survival. These findings highlight interesting potential implications for both control of respiratory virus infection and vaccine efficacy in the elderly.

**RDC response to virus infection**

DCs are hematopoietic origin cells of the monocytic cell lineage. These cells are generally recognized to be an exclusive cell type, since they have the capacity to initiate the primary adaptive immune response (mediated by T and B cells) to foreign antigens, including infectious agents. The importance of these cells is highlighted by the fact that the 2011 Nobel Prize in Physiology or Medicine was recently awarded to Ralph Steinman for his role in the identification and characterization of DCs (4, 5). DCs reside within tissues at body surfaces, such as the skin, gut, and respiratory tract mucosa. At these sites, these actively phagocytic cells act as sentinels, monitoring the site for the presence of foreign antigens, such as those derived from viruses. The tissue DCs respond to this encounter by capturing foreign antigen, processing the antigen to a form that can be recognized by T cells, becoming activated, and, importantly, migrating to the DLNs from the body’s surfaces. It is within the DLN that the DCs encounter T cells specific for the antigen/pathogen that they have captured and processed and, thereby, initiate the adaptive immune response (6).

Migration of activated tissue DCs from the site of infection, e.g., the lungs, to the DLN is an essential step in the induction of the adaptive immune response to the infectious agent. DC migration is chemokine regulated and, in part at least, dependent on the upregulation of expression of and signaling through the chemokine receptor CCR7, whose ligands (CCL19 and CCL21) are expressed by lymphatic endothelium draining the infected tissue (Figure 1 and ref. 7). A variety of stimuli (probably acting in concert) can stimulate tissue DC activation and, as a result, migration. These stimuli include cytokines, chemokines, and certain AA-derived metabolites, such as PGE₂ and leukotriene C₄ (LTC₄) (Figure 1). Of particular relevance to the report of Zhao and coworkers is the fact that another...
er lipid mediator derived from AA, PGD$_2$, has been previously shown to inhibit RDC migration out of the lungs (8, 9).

**AA metabolites and regulation of RDC migration**

PGD$_1$ and PGE$_2$ are AA metabolites generated through the action of 2 cyclooxygenase enzymes, the constitutively expressed COX-1 and the inducible COX-2, both of which catalyze the generation of PGH$_2$ (Figure 2). PGH$_2$ is in turn converted to specific biologically active prostanoids such as PGD$_2$ by cell type-specific prostanoid synthases, e.g., PGD$_2$ synthase (10). In the report from Zhao et al. (3), PGD$_2$ levels were shown to become progressively elevated with age in the bronchoalveolar lavage fluid (BALF) of naïve mice (i.e., prior to infection), suggesting an elevated level or at least activity of the constitutively expressed COX-1 enzyme with increasing age. Alternatively, the greater amount of PGD$_2$ observed in the lungs of aged mice could also reflect age-associated upregulation of COX-2 expression. Senescent cells or cells derived from aged mice produce, as a by-product of the hydro-
lysis of membrane sphingomyelin, substantially more of the intracellular sphingolipid second messenger ceramide than do their younger counterparts (11). The increased levels of ceramide mediate age-associated increases in COX-2 expression and, as a consequence, prostaglandins (e.g., PGD$_2$ and PGE$_2$) levels. The elevated basal level of PGD$_2$, detected by Zhao and coworkers in lungs of aged mice prior to infection (3), may be of biological significance, although the basal rate of RDC migration to the DLN (i.e., without an inflammatory stimulus) was not examined in these animals (Figure 1). Although it might be logistically challenging, an analysis of PGD$_2$ levels in the human lower respiratory tract as a function of age in individuals without preexisting acute or chronic pulmonary inflammation might be warranted to complement (and substantiate) the findings of Zhao and coworkers.

Not surprisingly, Zhao et al. report that PGD$_2$ levels increase in the BALF after respiratory virus infection (3), presumably reflecting upregulation of the inducible COX-2 enzyme in response to proinflammatory stimuli. However, it is noteworthy that, in young mice, the effect of infection on PGD$_2$ production was minimal, whereas, in aged mice, infection produced a greater increase in PGD$_2$ levels. Furthermore, in the two experimental infections investigated in detail (i.e., infection with SARS-CoV and IAV), PGD$_2$ levels in BALF were highest in mice infected with SARS-CoV, which likewise demonstrated the greatest mortality. The authors raise the possibility that pathogen-dependent differences in PGD$_2$ levels may reflect differences in the ability of particular viruses and specific viral gene products to regulate PGD$_2$ levels as part of their replication strategy. The pathogen sample size studied ($n = 2$) is too small to make a definitive statement concerning this hypothesis, and factors such as virus inoculum dose, target cell types for viral replication, and virus potency in stimulating host innate responses in the respiratory tract need to be further considered. Nevertheless, these findings suggest a possible mechanism to account for the enhanced susceptibility of elderly humans to severe infection with certain respiratory pathogens.

Reversal of reduced RDC migration and restoration of adaptive antiviral T cell immune responses by blockade of PGD$_2$ action

PGD$_2$ can be produced by a variety of cell types of nonhematopoietic (i.e., epithelial cells) and hematopoietic origin, with the latter including most prominently mast cells but also tissue DCs, in response to inflammatory stimuli (ref. 10 and Figure 1). Furthermore, PGD$_2$ can engage at least three classes of receptors: the ubiquitously expressed PGD$_2$ receptor (DP1; also known as PTGDR), the chemokine-related receptor CRTH2 (also known as GPR44), and the nuclear receptor PPAR-γ (12, 13). In the report from Zhao and coworkers (3), the analysis of the effect of PGD$_2$ antagonists with DP1 specificity (e.g., BW A868C) directly implicates DP1 as the receptor mediating suppression of RDC migration, interestingly, in aged but not young mice.

Figure 2
The pathways for eicosanoid biosynthesis. AA is released from cellular membrane phospholipids by phospholipases such as PLA2 in response to microbial infections and nonspecific stimuli, such as cytokines, hormones, and stress. Released AA can be converted to bioactive eicosanoids through the COX, lipooxygenase, or P450 epoxygenase pathways. Of interest, COX isozymes are composed of COX-1 (expression of which is constitutive) and COX-2 (expression of which is inducible). Both COX enzymes catalyze the formation of PGH$_2$, which is converted by cell-specific prostaglandin synthases to biologically active products, collectively known as prostanoids (e.g., PGD$_2$ and PGE$_2$). Expression of COX-2 is induced by proinflammatory mediators and inhibited by antiinflammatory cytokines. In addition, the basal activity of COX-2 and its products, prostanoids, is observed to be elevated in both senescent cells and cells derived from aged mice. This is associated with increased amounts of ceramide, which activates NF-κB activity, leading to the transcription of COX2 mRNA. Modified from reference 10. Adapted with permission from Trends in Molecular Medicine (ref. 10).
Although the basis for this differential effect of DP1 antagonism on RDC migration with age remains unclear, this is in keeping with previously published observations (8, 14). Importantly, release of the inhibitory action of PGD$_2$ on RDC migration by treatment with the DP1 antagonist prior to respiratory virus infection, notably SARS-CoV infection, in the aged mice resulted in the improved induction of virus-specific CD8$^+$ T cells at the priming site (i.e., the DLN) and, subsequently, the infected lung, which ultimately contributed to the reduced mortality after respiratory virus infection.

**PGD$_2$ controls CCR7 expression on RDCs from aged mice**

Mechanistically, Zhao et al. also provide evidence that PGD$_2$ acts to inhibit RDC migration in aged mice by regulating (reducing) the level of expression of CCR7 on migratory RDCs in lungs as well as the frequency of CCR7$^+$ RDCs accumulating in inflamed DLNs early in infection (ref. 3 and Figure 1). As the authors suggest, regulation of expression of the critical chemokine receptor necessary for RDC migration out of the infected lungs is likely to be one of several distinct mechanisms by which a prostanoid, such as PGD$_2$, can act on RDC maturation and subsequent migration. In this regard, it would have been of considerable interest to evaluate, in the lungs of aged mice, the expression of other AA metabolites, notably PGE$_2$ and LTC$_4$, which can antagonize the effects of PGD$_2$ (15, 16), and the effect of infection with the various viral pathogens on the production of these proinflammatory AA-derived lipid mediators. In this context, Zhao et al. demonstrate that administration of PGE$_2$ to the respiratory tract of aged mice does not reverse the reduced RDC migration (3).

**Boosting mucosal vaccine efficacy in the elderly**

The report from Zhao et al. in this issue of the *JCI* (3) offers a novel explanation for the increased susceptibility of the elderly to respiratory virus infections. Perhaps more importantly, these results may have therapeutic implications, as they suggest a strategy for boosting immune responses in the elderly. Although these findings do not bear on the poor response of the elderly to parenteral immunization, they do provide investigators with a new and potentially important target for investigation and manipulation, with the aim of boosting the efficacy of mucosal vaccination against respiratory viruses in the elderly. A novel mucosal vaccine formulation that included an adjuvant capable of enhancing migration of RDCs in the elderly, such as a PGD$_2$ inhibitor, could result in improvement of the response to mucosal-administered vaccines in the elderly and lead to the use of live-attenuated virus vaccines in this population.

**Acknowledgments**

We thank members of the Braciale laboratory for helpful discussions. This work is supported by grants from the NIH (RO1 AI-15608, RO1 AI-37293, RO1 HL-33391, and U-19 AI-83024) to T.J. Braciale.

Address correspondence to: Thomas J. Braciale, Carter Immunology Center, University of Virginia, PO Box 801386, Charlottesville, Virginia 22908, USA. Phone: 434.924.1219; Fax: 434.924.1221; E-mail: tjb2r@virginia.edu.